Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa (NASDAQ: ANIX) announced a presentation on its ovarian cancer CAR-T therapy, lira-cel, at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, May 6–9, 2026.
The presentation will cover the Phase 1 trial design, objectives, and the current status, with the company noting that lira-cel continues to show positive survival data in the ongoing study.
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Amit Kumar, chairman and CEO, will present at RedChip's virtual Biotech Resurgence conference on April 16, 2026 at 3:30 pm ET.
The presentation will review the company, its Phase 1 breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants, and ovarian CAR-T therapy lira-cel showing positive survival data in an ongoing Phase 1 trial. The session includes a live Q&A for investors and registration details.
Anixa Biosciences (NASDAQ: ANIX) announced Dr. Amit Kumar, chairman and CEO, will present at the Water Tower Research Insights Conference on April 14, 2026 at 12:30 pm ET. The virtual presentation will cover company strategy, clinical programs, and recent trial highlights.
Key clinical updates noted include a breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants in a Phase 1 trial, and ongoing Phase 1 ovarian CAR-T therapy lira-cel reporting positive survival data.
Anixa Biosciences (NASDAQ: ANIX) said its CEO Dr. Amit Kumar discussed the company’s advancing immunotherapy pipeline on Smart Money Circle on April 6, 2026. Key clinical updates: the breast cancer vaccine completed Phase 1 meeting primary endpoints with protocol-defined immune responses in 74% of participants, and the ovarian CAR-T therapy lira-cel is showing positive survival data in an ongoing Phase 1 trial.
The interview highlights clinical progress across both programs and ongoing development work for potential next steps.
Anixa Biosciences (NASDAQ: ANIX) reported positive final Phase 1 results for its α-lactalbumin breast cancer vaccine and has engaged Cytovance Biologics to produce cGMP clinical material for a planned Phase 2 trial.
The Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants.
Anixa (NASDAQ: ANIX) announced that Dr. Robert Wenham of Moffitt Cancer Center will present an update on the company’s Phase 1 ovarian cancer CAR-T trial (lira-cel) at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, April 10–13, 2026 in San Juan, Puerto Rico.
The presentation will cover the trial design, objectives, and current status of the autologous T-cell therapy targeting FSHR in recurrent ovarian cancer.
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar is featured on the Water Tower Research Healthcare Happenings podcast on March 12, 2026. Dr. Kumar discusses positive clinical trial data for the breast cancer vaccine and ovarian cancer CAR-T therapy, plus future plans and the company's financial condition. The podcast is available at the Water Tower Research media page.
Anixa Biosciences (NASDAQ: ANIX) announced the Korean Ministry of Intellectual Property issued a Notice of Allowance for a patent titled "Vaccine Adjuvants and Formulations" covering its breast cancer vaccine technology, licensed exclusively from Cleveland Clinic.
The allowance expands international IP coverage, complements U.S. patents, and follows a Phase 1 trial that was safe, met primary endpoints, and generated immune responses in 74% of participants, supporting further clinical development and potential future commercialization outside the U.S.
Anixa (NASDAQ: ANIX) will hold its 2026 Annual Meeting of Stockholders virtually on March 10, 2026 at 10:00 a.m. PT, open to all interested parties. Following formal business, CEO Dr. Amit Kumar will present clinical and regulatory updates across the oncology pipeline.
Key highlights include a regulatory approval for substantial dose escalation in the ongoing Phase 1 ovarian cancer CAR-T trial and final Phase 1 breast cancer vaccine data that met primary endpoints with favorable tolerability and protocol-defined immune responses in the majority of participants.
The presentation will conclude with a live question-and-answer session. Access: www.virtualshareholdermeeting.com/ANIX2026.
Anixa (NASDAQ: ANIX) announced that Dr. Jose Conejo-Garcia, co‑inventor of Anixa's FSHR‑mediated CAR‑T technology, will keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat on March 6, 2026. His keynote will discuss Anixa's ongoing Phase 1 trial of liraltagene autoleucel (lira‑cel), which uses the FSHR‑mediated CAR‑T approach first discovered by Dr. Conejo‑Garcia and team.
The SCTR 2026 Retreat will convene researchers, clinicians, and industry to showcase advances in cell therapy, immunotherapy, oncology, and cellular manufacturing.